<DOC>
	<DOCNO>NCT00193453</DOCNO>
	<brief_summary>This purpose study evaluate role gemcitabine docetaxel , well tolerate chemotherapy regimen treatment advance non-small cell lung cancer ( NSCLC ) , combination novel agent cetuximab .</brief_summary>
	<brief_title>Gemcitabine , Docetaxel , Cetuximab Patients With Unresectable Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility patient receive : - Docetaxel + Gemcitabine + Cetuximab</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>To include study , must meet following criterion : 18 year age old Nonsmall cell lung cancer confirm biopsy Unresectable stage III IV disease Measurable disease Must receive prior chemotherapy lung cancer Able perform activity daily live without considerable assistance Adequate bone marrow , kidney , liver function Signed informed consent You participate study follow apply : History serious heart disease within six month prior study entry Prior treatment agent target EGFR pathway History uncontrolled significant disease Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Lung Cancer</keyword>
</DOC>